Loading company
Vaxcyte, Inc.
PCVX · Nasdaq · ·
Next earnings: November 3, 2026
$56.71-2.6%Sep 29 close
- 1M
- -5.2%
- 6M
- +3.2%
- 1Y
- +57.4%
- 5Y
- +116.6%
PCVX · Nasdaq · ·
Next earnings: November 3, 2026
$56.71-2.6%Sep 29 close
Vaxcyte, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$284.3M | -$166.6M | -70.68% |
| Profit per share | -$1.97 | -$1.22 | -61.48% |
| Free Cash Flow | -$236.8M | -$123M | -92.55% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Vaxcyte, Inc. has no earnings call transcript available.
“With the VAX-31 OPUS-1, OPUS-2 and OPUS-3 Phase 3 trials and the VAX-31 Phase 2 infant study fully enrolled, we expect a series of meaningful clinical study readouts across our adult and infant pneumococcal conjugate vaccines (PCV) franchise over the next 12 months,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Vaxcyte, Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.